Novel method could determine which lymphoma patients will respond to CAR T-cell therapy
A new high-throughput approach has shown how patients whose tumours express CD58 are more likely to respond to CAR T-cell therapy.
List view / Grid view
A new high-throughput approach has shown how patients whose tumours express CD58 are more likely to respond to CAR T-cell therapy.
CAR T cells have shown incredible promise in the clinic, but there is still room for advancement. One avenue for improvement is through modification of the CAR design. However, given the number of exchangeable domains, testing all variations can present a hurdle. In this article, Dr Sarwish Rafiq, Assistant Professor in…
The new nanotechnology left six of 10 mice with lymphoma tumour-free and was effective in melanoma when combined with existing drugs.
Scientists at the New York University (NYU) Abu Dhabi have used nuclear magnetic resonance (NMR) techniques to determine the structure of a specific nanobody, Nb23. Drug Target Review’s Victoria Rees spoke with lead researcher Professor Gennaro Esposito to find out how their findings could lead to a better understanding of…
Dr Björn Frendeus outlines how the growing biology surrounding the inhibitory Fc receptor FcγRIIb defines a target for improving existing and future antibody treatments.
In pre-clinical studies, researchers showed that cord blood-derived natural killer cells and a bispecific antibody eliminated lymphoma cells.
A new form of CAR T-cell therapy has shown promise in mice models to treat blood cancers; this article delves into the development behind the therapy.
In this article, we outline three recent studies that have advanced the potential uses of CRISPR in the biomedical field.
By combining natural killer cells with a new molecule called Sialyl-Lewis X, researchers were able to treat lymphoma in mice.
Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
Researchers have created a method to activate CAR T cells with blue LED light to successfully combat solid tumours in mice.
PROTAC drugs that safely and effectively target leukaemia and lymphoma cells have been developed by researchers.
A new study shows the ways in which epigenetic mechanisms control the activity of genes and may have an impact on the future treatment of certain cancers.
Researchers at MIT have identified a way to stimulate a particular stem cell in order the hasten the regeneration of red blood cells...
Scientists have discovered how the most important gene in preventing human cancer, p53, is able to stop the development of lymphoma and potentially other types of cancer...